Journal Information

Statistics

Follow this link to access the full text of the article

Letter to the Editor
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
F. Barataa, H. Queirogab, E. Teixeirac, T. Almodovard, M. Soarese, B. Parentef, J.C. Mellidezg, P. Alvesc, A. Antunesh,
Corresponding author
ana.antunes@roche.com

Corresponding author.
a Centro Hospitalar e Universitário de Coimbra, Portugal
b Centro Hospitalar São João, Porto, Portugal
c Centro Hospitalar Lisboa Norte, Lisboa, Portugal
d Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal
e Instituto Português de Oncologia Francisco Gentil, Porto, Portugal
f Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
g Centro Hospitalar Baixo Vouga, Aveiro, Portugal
h Roche Farmacêutica Química, Portugal
Read
2197
Times
was read the article
819
Total PDF
1126
Total HTML
252
Total EPUB
Share statistics
Article information
ISSN: 25310437
Original language: English
The statistics are updated each day
Year/Month Html Pdf Epub Total
2022 January 43 34 9 86
2021 December 32 41 11 84
2021 November 45 36 13 94
2021 October 42 53 14 109
2021 September 42 38 10 90
2021 August 43 36 10 89
2021 July 39 32 9 80
2021 June 50 46 13 109
2021 May 33 54 18 105
2021 April 210 178 62 450
2021 March 86 64 24 174
2021 February 82 71 12 165
2021 January 43 29 11 83
2020 December 40 18 6 64
2020 November 54 25 10 89
2020 October 146 37 12 195
2020 September 96 27 8 131
Show all

Follow this link to access the full text of the article

Pulmonology

Subscribe to our newsletter

Are you a health professional able to prescribe or dispense drugs?